The Journal of Allergy and Clinical Immunology
Volume 121, Issue 1 , Pages 30-37.e6, January 2008

Molecular phenotyping of severe asthma using pattern recognition of bronchoalveolar lavage–derived cytokines

  • Allan R. Brasier, MD

      Affiliations

    • Department of Internal Medicine, University of Texas Medical Branch, Galveston, Tex
    • Sealy Center for Molecular Medicine, Galveston, Tex
    • Corresponding Author InformationReprint requests: Allan R. Brasier, MD, MRB 8.128, University of Texas Medical Branch, 301 University Blvd, Galveston, TX 77555-1060.
  • ,
  • Sundar Victor, MS

      Affiliations

    • Department of Internal Medicine, University of Texas Medical Branch, Galveston, Tex
    • Sealy Center for Molecular Medicine, Galveston, Tex
  • ,
  • Gary Boetticher, PhD

      Affiliations

    • Department of Computer Science, University of Houston-Clear Lake, Clear Lake, Tex
  • ,
  • Hyunsu Ju, PhD

      Affiliations

    • Sealy Center on Aging, Galveston, Tex
  • ,
  • Chang Lee, MS

      Affiliations

    • Department of Internal Medicine, University of Texas Medical Branch, Galveston, Tex
  • ,
  • Eugene R. Bleecker, MD

      Affiliations

    • Department of Medicine, Wake Forest University School of Medicine, Winston-Salem, NC
  • ,
  • Mario Castro, MD

      Affiliations

    • Washington University in St Louis, St Louis, Mo
  • ,
  • William W. Busse, MD

      Affiliations

    • Department of Medicine, University of Wisconsin, Madison, Wis
  • ,
  • William J. Calhoun, MD

      Affiliations

    • Department of Internal Medicine, University of Texas Medical Branch, Galveston, Tex
    • Sealy Center for Molecular Medicine, Galveston, Tex

Received 15 May 2007; received in revised form 10 October 2007; accepted 16 October 2007.

Background

Asthma is a heterogeneous clinical disorder. Methods for objective identification of disease subtypes will focus on clinical interventions and help identify causative pathways. Few studies have explored phenotypes at a molecular level.

Objective

We sought to discriminate asthma phenotypes on the basis of cytokine profiles in bronchoalveolar lavage (BAL) samples from patients with mild-moderate and severe asthma.

Methods

Twenty-five cytokines were measured in BAL samples of 84 patients (41 severe, 43 mild-moderate) using bead-based multiplex immunoassays. The normalized data were subjected to statistical and informatics analysis.

Results

Four groups of asthmatic profiles could be identified on the basis of unsupervised analysis (hierarchical clustering) that were independent of treatment. One group, enriched in patients with severe asthma, showed differences in BAL cellular content, reductions in baseline pulmonary function, and enhanced response to methacholine provocation. Ten cytokines were identified that accurately predicted this group. Classification methods for predicting methacholine sensitivity were developed. The best model analysis predicted hyperresponders with 88% accuracy in 10 trials by using a 10-fold cross-validation. The cytokines that contributed to this model were IL-2, IL-4, and IL-5. On the basis of this classifier, 3 distinct hyperresponder classes were identified that varied in BAL eosinophil count and PC20 methacholine.

Conclusion

Cytokine expression patterns in BAL can be used to identify distinct types of asthma and identify distinct subsets of methacholine hyperresponders. Further biomarker discovery in BAL may be informative.

Key words: Asthma, inflammation, cytokines, phenotypes, ELISA, hierarchical clustering, bioinformatics, class discovery

Abbreviations used: ATS, American Thoracic Society, BAL, Bronchoalveolar lavage, FVC, Forced vital capacity, IL-1Ra, IL-1 receptor antagonist, LR, Low responder, MCP, Monocyte chemoattractant protein, MIP, Macrophage inflammatory protein, MOP, Manual of procedures, SARP, Severe Asthma Research Program

 

 Supported by National Institutes of Health grant AI062885 (A.R.B.), a National Institute of Environmental Health Sciences Pilot Project (A.R.B.), National Heart, Lung, and Blood Institute contract BAA-HL-02-04 (A. Kurosky), HL69130 US Severe Asthma Research Program (W.J.C.), and the Integrated Health Science Facility Core P30 ES06676 (to J. Halpert, UTMB).

 Disclosure of potential conflict of interest: W. W. Busse has consulting arrangements with Genentech/Novartis, Isis, GlaxoSmithKline, Altanta, Wyeth, Pfizer, Dynavax, Centocor, Johnson and Johnson, Hoffman LaRoche, Alza CV Therapeutics, Takeda, Abbott, and Millenium; has received grant support from Novartis, Dynavax, Wyeth, Centocor, GlaxoSmithKline, Medicinova, Sanofi-Aventis, Dey, Pfizer, Astellas Pharma, Inflazyme, and Biowa; and is on the speakers' bureau for Novartis, Merck, and AstraZeneca. W. J. Calhoun has received grant support from Sepracor. The rest of the authors have declared that they have no conflict of interest.

PII: S0091-6749(07)01960-4

doi:10.1016/j.jaci.2007.10.015

The Journal of Allergy and Clinical Immunology
Volume 121, Issue 1 , Pages 30-37.e6, January 2008